BB BIOTECH shareholders approve proposal submitted by the Board of
Directors>
BB BIOTECH shareholders approve proposal submitted by the Board of Directors
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ Shareholders at BB BIOTECH's extraordinary general meeting on July 6,2009 approved the proposal submitted by the Board of Directors.The shareholders confirmed the resolution to initiate a sixth sharebuyback program. BB BIOTECH intends to repurchase and cancel over thenext three years up to 1.825 million of its registered shares, whichcorresponds to 10% of total share capital. The company's purchase ofthe shares will be possible within three years. The proposedreduction in the number of outstanding registered shares willincrease earnings per share and should also reduce the discountbetween the market price and the reported net asset value.The extraordinary general meeting became necessary due to a change ofthe rules for share buyback programs by the Swiss ÿbernahmekommissionon April 8th 2009.For further information:Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht,SwitzerlandAnja Stubenrauch, Tel. +41 44 267 67 00Company profile:BB BIOTECH invests in companies in the fast growing market ofbiotechnology and is one of the world's largest investors in thissector. BB BIOTECH is listed in Switzerland, Germany and Italy. Itsinvestments are focused on listed companies that are developing andcommercializing novel medical treatments and cures. BB BIOTECH'sinvestment selection process is guided by the fundamental researchand analysis of physicians and molecular biologists. Its Board ofDirectors has many years of experience in industry and science. --- End of Message ---BB BIOTECH AGVordergasse 3 Schaffhausen SwitzerlandWKN: AONFN3; ISIN: CH0038389992; Index: SBIOM, IGSP, SLIFE;Listed: Investment Companies in SIX Swiss Exchange;
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="Drilling Update>
">
" alt="Final Net Asset Value(s)>
">Datum: 06.07.2009 - 12:02 Uhr
Sprache: Deutsch
News-ID 1002137
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
London
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 370 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BB BIOTECH shareholders approve proposal submitted by the Board of
Directors>
"
steht unter der journalistisch-redaktionellen Verantwortung von
BB BIOTECH AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
